

<b>C CONSOLIDATED STATEMENT OF FINANCIAL PERFORMANCE</b>	Six months ended 30-Sep-14 \$NZ'000	9-Aug-13 to 30-Sep-13 \$NZ'000
Revenue	414	-
Cost of sales	(293)	-
<b>Gross profit</b>	121	-
Interest income	3	-
Employee benefit expenses and directors fees	(359)	-
Administration and other operating expenses	(246)	-
Finance costs - interest expense on convertible note at amortised cost	(10)	-
<b>Loss from ordinary activities before income tax</b>	(491)	-
Income tax benefit/ (expense)	-	-
<b>Loss for the period</b>	(491)	-
<b>Other comprehensive income</b>		-
Exchange difference on translating foreign controlled entities operations	416	-
<b>Other comprehensive income for the period</b>	416	-
<b>Total comprehensive income for the period</b>	(75)	-
Total number of shares on issue	144,446,666	100
Weighted average number of shares on issue	141,647,161	100
<b>Earnings per share for profit attributable to the equity holders of the Company</b>		
Basic EPS (cents)	(0.35)	-
Diluted EPS (cents)	(0.33)	-

<b>D CONSOLIDATED STATEMENT OF FINANCIAL POSITION</b>	At at 30-Sep-14 \$NZ'000	At at 30-Sep-13 \$NZ'000
<b>CURRENT ASSETS:</b>		
Cash and cash equivalents	1,471	-
Trade and other receivables	284	-
Goods and services tax recoverable	44	-
Inventories	874	1,012
Other assets	20	
<b>TOTAL CURRENT ASSETS</b>	2,693	1,012
<b>NON-CURRENT ASSETS</b>		
Trade and other receivables	-	-
Property, plant and equipment	3	-
Intangible Assets	8,330	8,165
<b>TOTAL NON-CURRENT ASSETS</b>	8,333	8,165
<b>TOTAL ASSETS</b>	11,026	9,177
<b>CURRENT LIABILITIES</b>		
Trade and other payables	236	-
Borrowings		-
Employee benefits	25	-
<b>TOTAL CURRENT LIABILITIES</b>	261	-
<b>TOTAL LIABILITIES</b>	261	-
<b>NET ASSETS</b>	10,765	9,177
<b>EQUITY</b>		
Share capital	12,921	9,177
Reserves (i) Foreign currency translation reserve	(217)	-
(ii) Share option reserve	132	-
Accumulated Losses	(2,071)	-
<b>TOTAL EQUITY ATTRIBUTABLE TO EQUITY HOLDERS</b>	10,765	9,177

Non-controlling interests	-	-
<b>TOTAL EQUITY</b>	<b>10,765</b>	<b>9,177</b>

**Net tangible assets per share (cents)** 1.69 1,012,362

<b>E STATEMENT OF CHANGE IN EQUITY</b>	Six months ended 30-Sep-14 \$NZ'000	9-Aug-13 to 30-Sep-13 \$NZ'000
Loss for the period	(491)	-
Other comprehensive income/ (loss) for the period	416	-
<b>Movement in equity for the period</b>		
Issue of ordinary shares	426	9,177
Increases in share option reserves	13	-
<b>EQUITY AT BEGINNING OF PERIOD</b>	<b>10,402</b>	<b>-</b>
<b>EQUITY AT END OF PERIOD</b>	<b>10,766</b>	<b>9,177</b>

<b>F CONSOLIDATED STATEMENT OF CASHFLOWS</b>	Six months ended 30-Sep-14 \$NZ'000	9-Aug-13 to 30-Sep-13 \$NZ'000
<b>CASH FLOWS RELATING TO OPERATING ACTIVITIES</b>		
Receipts from customers	150	-
Interest received	3	-
Payments to suppliers and employees	(798)	-
<b>NET CASH FLOWS FROM OPERATING ACTIVITIES</b>	<b>(645)</b>	<b>-</b>
<b>CASH FLOWS RELATING TO INVESTING ACTIVITIES</b>		
Purchase of intellectual property	(338)	-
Purchase of equipment	-	-
<b>NET CASH FLOWS FROM INVESTING ACTIVITIES</b>	<b>(338)</b>	<b>-</b>
<b>CASH FLOWS RELATED TO FINANCING ACTIVITIES</b>		
Cash proceeds from issue of shares	439	-
Repayment of convertible notes	(773)	-
Share issue costs	(52)	-
<b>NET CASH FLOWS FROM FINANCING ACTIVITIES</b>	<b>(386)</b>	<b>-</b>
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>(1,369)</b>	
Cash at beginning of the period	2,840	-
<b>CASH AT END OF THE PERIOD</b>	<b>1,471</b>	<b>-</b>

**G MATERIAL ACQUISITIONS OF SUBSIDIARIES** N/A

**H MATERIAL DISPOSALS OF SUBSIDIARIES** N/A

**I MATERIAL INVESTMENT IN JOINTLY CONTROLLED ENTITY** N/A

**J ISSUED AND QUOTED SECURITIES AT END OF CURRENT PERIOD**

Category of Securities Issued	Number	Quoted		
<b>ORDINARY SHARES:</b>				
Total number of share in issue	144,446,666	144,446,666		
Issued during current period	4,290,000	4,290,000		
	<b>Issued</b>	<b>Quoted</b>	<b>Exercise Price</b>	<b>Expiry Date</b>
<b>OPTIONS</b>				
Total number of share in issue	6,750,000	-	\$.10	27 March 2018

Issued during current period

-----  
- -  
-----

## K REPORTS FOR OPERATING SEGMENTS

The Group operates in one operating segment. It owns the rights to the Truscreen Cervical Cancer screening system. The system comprises a medical device and process designed to detect the presence in real time of precancerous and cancerous tissue on the cervix.

The Group is in the process of obtaining regulatory approvals. On the granting of these approvals the Group anticipates the ability to increase distribution and revenues. It is anticipated revenues will be obtained largely from Asia, Europe, Central and South America. The limited revenues to date have been obtained in anticipation of these approvals. These revenues have been obtained from distributors.

Two major customers each contributed more than 10% of the Group's revenue in the six months to 30 September 2014:

- One customer provided revenue of \$343,005 (83 %);
- The other customer provided revenue of \$59,347 (14%).

No additional disclosure is required in the interim financial statements as the Group has one reportable segment

## L COMMENTS BY DIRECTORS

If no report in any section, state NIL. If insufficient space below, provide details in the form of notes to be attached to this report.

- (a) Material factors affecting the revenues and expenses of the group for the current period

-----  
**Refer to Commentary.**  
-----

- (b) Significant trends or events since end of current period

-----  
**Refer to Commentary.**  
-----

- (c) Changes in accounting policies since last Annual Report and/or last Half Yearly to be disclosed

-----  
**None.**  
-----

- (d) Critical Accounting Policies - Management believes the following to be critical accounting policies. That is they are both important to the portrayal of the Issuer's financial condition and results, as they require management to make judgments and estimates about matters that they are inherently uncertain

-----  
**None.**  
-----

- (e) Management's discussion and analysis of financial condition, result and/or operations (optional) - this section should contain forward looking statements that should outline where these involve risk and uncertainty

-----  
**Refer to Commentary.**  
-----

- (f) Other comments

-----  
**None.**  
-----

-----  
(signed by) Authorised Officer of Listed Issuer

-----  
(date)